Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: A systematic review

References

• Berger B, Belka C. Evidence-based radiation oncology: Ooesophagus. Radiother Oncol 2009;92:276–90.
   PubMed Web of Science ®Google Scholar
• Homs MY, Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006; 4:CD004063.
   Google Scholar
• Blazeby JM. Measurement of outcome. Surg Oncol 2001;10:127–33.
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials – does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502–11.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane collaboration 2009 Sep.
   Google Scholar
• Bottomley A, Jones D, Claassens L. Patient-reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer 2009;45:347–53.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81.
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Alderson D, Winstone K, Steyn R, Hammerlid E, Arraras J, et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur J Cancer 1996;32A:1912–7.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 2002;94:641–6.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210–6.
   PubMed Web of Science ®Google Scholar
• Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival. Cancer 1996;77:1978–85.
   PubMed Web of Science ®Google Scholar
• Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005; 18:131–9.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Walpole ET, Burmeister EA, Thomas J, Thomson DB, Harvey JA, et al. Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. Int J Clin Oncol 2005;10:256–61.
   PubMedGoogle Scholar
• Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, et al. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 2005;20:618–23.
   PubMed Web of Science ®Google Scholar
• Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: Response, toxicity, quality of life and survival. Ann Oncol 2002;13:721–9.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: Results of a randomised phase III trial. Qual Life Res 2009;18:853–61.
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450–7.
   PubMed Web of Science ®Google Scholar
• Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609–16.
   PubMed Web of Science ®Google Scholar
• Frobe A, Jones G, Jaksic B, Bokulic T, Budanec M, Iva M, et al. Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus. Dis Esophagus 2009;22: 513–8.
   PubMed Web of Science ®Google Scholar
• Harbord M, Dawes RFH, Barr H, Giovannini M, Viens P, Eysselein V, et al. Palliation of patients with dysphagia due to advanced esophageal cancer by endoscopic injection of cisplatin/epinephrine injectable gel. Gastrointest Endosc 2002;56:644–51.
   PubMed Web of Science ®Google Scholar
• Hayter CR, Huff-Winters C, Paszat L, Youssef YM, Shelley WE, Schulze K. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol 2000;56: 329–33.
   PubMed Web of Science ®Google Scholar
• Homs MY, Essink-Bot ML, Borsboom GJ, Steyerberg EW, Siersema PD, Dutch SIREC Study Group. Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004;40:1862–71.
   PubMed Web of Science ®Google Scholar
• Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: Multicentre randomised trial. Lancet 2004;364:1497–504.
   PubMed Web of Science ®Google Scholar
• Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17: 3270–5.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, et al. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 2002;32:115–23.
   PubMedGoogle Scholar
• Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:29–34.
   PubMed Web of Science ®Google Scholar
• Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J, DeBoer G, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2008;20:53–60.
   PubMed Web of Science ®Google Scholar
• Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol 2010;21: 2213–9.
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996–2004.
   PubMed Web of Science ®Google Scholar
• Rupinski M, Zagorowicz E, Regula J, Fijuth J, Kraszewska E, Polkowski M, et al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II). Am J Gastroenterol 2011;106: 1612–20.
   PubMed Web of Science ®Google Scholar
• Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am J Gastroenterol 2009;104:1674–85.
   PubMed Web of Science ®Google Scholar
• Spencer GM, Thorpe SM, Blackman GM, Solano J, Tobias JS, Lovat LB, et al. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: A randomised study. Gut 2002;50:224–7.
   PubMed Web of Science ®Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976–83.
   PubMed Web of Science ®Google Scholar
• Taeb J, Artru P, Baujat B, Mabro M, Carola E, Maindrault F, et al. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur J Cancer 2002;38:661–6.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002;13:1568–75.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24:4991–7.
   PubMed Web of Science ®Google Scholar
• van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der GA. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: A phase II study. Br J Cancer 2007;96:1348–52.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261–7.
   PubMed Web of Science ®Google Scholar
• O’Hanlon DM, Harkin M, Karat D, Sergeant T, Hayes N, Griffin SM. Quality-of-life assessment in patients undergoing treatment for oesophageal carcinoma. Br J Surg 1995;82: 1682–5.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62:1034–8.
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Nag S, Herskovic A, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 1997;38:127–32.
   PubMed Web of Science ®Google Scholar
• Young T, de Haes H, Curran D, Fayers P, Brandberg Y, Vanvoorden V, et al. Guidelines for assessing quality of life in EORTC clinical trials. Available from: http://groups.eortc.be/qol/manuals [cited 2012 Oct 3].
   Google Scholar
• Blazeby JM, Kavadas V, Vickery CW, Greenwood R, Berrisford RG, Alderson D. A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res 2005;14:387–93.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Available from: http://groups.eortc.be/qol/manuals [cited 2012 Oct 3].
   Google Scholar
• Blazeby JM, Nicklin J, Brookes ST, Winstone K, Alderson D. Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer 2003;89:497–501.
   PubMed Web of Science ®Google Scholar
• Ahlner-Elmqvist M, Bjordal K, Jordhoy MS, Kaasa S, Jannert M. Characteristics and implications of attrition in health-related quality of life studies in palliative care. Palliat Med 2009;23:432–40.
   PubMed Web of Science ®Google Scholar
• Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008;44:1793–8.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44.
   PubMed Web of Science ®Google Scholar